Higher doses of semaglutide (2.4 mg weekly, Wegovy) have been specifically licensed for weight management in individuals with obesity, reflecting the medication's potent effects on appetite regulation
Activation of tubular epithelial cells in diabetic nephropathy
Retatrutide is distinguished by its triple agonist mechanism, simultaneously targeting GLP-1, GIP, and glucagon receptors
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
She strives to achieve subtle yet transformative results that boost confidence and promote youthful appearance
Heart rate changes observed during treatment return to pre-treatment baseline after discontinuation
